Activation of coagulation and proinflammatory pathways in thrombosis with thrombocytopenia syndrome and following COVID-19 vaccination.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
23 10 2023
23 10 2023
Historique:
received:
16
05
2023
accepted:
16
10
2023
medline:
27
10
2023
pubmed:
24
10
2023
entrez:
23
10
2023
Statut:
epublish
Résumé
Thrombosis with thrombocytopenia syndrome (TTS) is a rare but potentially severe adverse event following immunization with adenovirus vector-based COVID-19 vaccines such as Ad26.COV2.S (Janssen) and ChAdOx1 (AstraZeneca). However, no case of TTS has been reported in over 1.5 million individuals who received a second immunization with Ad26.COV2.S in the United States. Here we utilize transcriptomic and proteomic profiling to compare individuals who receive two doses of Ad26.COV2.S with those vaccinated with BNT162b2 or mRNA-1273. Initial Ad26.COV2.S vaccination induces transient activation of platelet and coagulation and innate immune pathways that resolve by day 7; by contrast, patients with TTS show robust upregulation of these pathways on days 15-19 following initial Ad26.COV2.S vaccination. Meanwhile, a second immunization or a reduced initial dose of Ad26.COV2.S induces lower activation of these pathways than does the full initial dose. Our data suggest a role of coagulation and proinflammatory pathways in TTS pathogenesis, which may help optimize vaccination regimens to reduce TTS risk.
Identifiants
pubmed: 37872311
doi: 10.1038/s41467-023-42559-x
pii: 10.1038/s41467-023-42559-x
pmc: PMC10593859
doi:
Substances chimiques
Ad26COVS1
JT2NS6183B
BNT162 Vaccine
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
6703Informations de copyright
© 2023. Springer Nature Limited.
Références
Hum Vaccin Immunother. 2022 Dec 31;18(1):2036556
pubmed: 35254213
Front Immunol. 2021 Nov 23;12:779453
pubmed: 34887867
Vaccine. 2011 Jul 18;29(32):5203-9
pubmed: 21619905
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
J Infect Dis. 2015 Feb 15;211(4):518-28
pubmed: 25165165
JAMA Netw Open. 2022 Aug 1;5(8):e2226335
pubmed: 35947380
Front Immunol. 2022 May 10;13:879157
pubmed: 35619694
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Res Pract Thromb Haemost. 2022 Jun 21;6(4):e12750
pubmed: 35769629
Genome Biol. 2014;15(12):550
pubmed: 25516281
Cell. 2021 Jun 24;184(13):3467-3473.e11
pubmed: 34133941
Sci Rep. 2018 May 30;8(1):8382
pubmed: 29849057
JAMA. 2021 Apr 20;325(15):1535-1544
pubmed: 33704352
Cell. 2017 May 18;169(5):862-877.e17
pubmed: 28502771
JACC Basic Transl Sci. 2022 May;7(5):425-441
pubmed: 35530264
N Engl J Med. 2021 Aug 5;385(6):570-571
pubmed: 34077639
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Commun. 2022 Sep 5;13(1):5206
pubmed: 36064843
Curr Protoc. 2021 Mar;1(3):e90
pubmed: 33780170
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
Nat Immunol. 2014 Feb;15(2):195-204
pubmed: 24336226
JAMA. 2021 Jun 22;325(24):2448-2456
pubmed: 33929487
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Lancet. 2021 Aug 14;398(10300):577-578
pubmed: 34329583
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Sci Adv. 2021 Dec 03;7(49):eabl8213
pubmed: 34851659
N Engl J Med. 2021 Jun 3;384(22):2124-2130
pubmed: 33835768
Lancet. 2022 Mar 19;399(10330):1141-1153
pubmed: 35305740
Genome Med. 2012 Mar 29;4(3):28
pubmed: 22458606
Ann Intern Med. 2021 Oct;174(10):1480-1482
pubmed: 34181446
Lancet Glob Health. 2022 Jan;10(1):e33-e34
pubmed: 34919849
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
Ann Intern Med. 2022 Apr;175(4):513-522
pubmed: 35038274